GEN Exclusives

More »

GEN News Highlights

More »
Sep 28, 2006

AskBio and GSK Ink Gene Therapy Agreement

  • Asklepios Biopharmaceutical entered into a cross license agreement with GlaxoSmithKline to develop and commercialize gene therapy-based treatments.

    Through the agreement, AskBio will gain exclusive access to selected recombinant adeno-associated virus vector serotypes that GSK licensed from the University of Pennsylvania for the treatment of three orphan drug indications, including muscular dystrophy, heart failure suffered by muscular dystrophy patients, and hemophilia B.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?